Enhancing PrEP Uptake and Retention Among Latine Transgender Women and Gay, Bisexual, and Other Men Who Have Sex With Men Using Long-Acting Injectable PrEP (lenacapavir)

What this Trial Is About

This research aims to test a culturally tailored, community-delivered program using long-acting injectable PrEP (lenacapavir) to improve HIV prevention among Latine gay and bisexual men (GBM) and transgender women (TGW). The study evaluates whether this approach increases persistence on lenacapavir compared to historical data at the Duke PrEP Clinic, focusing on these specific populations in the Southern United States. Participants will receive lenacapavir injections through a community-based program integrated at El Centro Hispano facilities. Peer Navigators will provide culturally appropriate support to help with PrEP uptake, adherence, and persistence. This hybrid implementation study collects data on both the clinical intervention and how well the program is delivered over time. During the study, participants will be monitored for up to one year, including identification of barriers, facilitators, and recommendations related to lenacapavir delivery at the community organization. Researchers will assess acceptability of the intervention through participant responses and measure feasibility from the providers' perspective. The total participation duration may vary, with ongoing assessments to understand program sustainability and participant experiences.

Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP